CN1376072A - 利用胰高血糖素样肽-1或其生物活性类似物代谢介入以改善缺血性及再灌注大脑的功能 - Google Patents
利用胰高血糖素样肽-1或其生物活性类似物代谢介入以改善缺血性及再灌注大脑的功能 Download PDFInfo
- Publication number
- CN1376072A CN1376072A CN00806935A CN00806935A CN1376072A CN 1376072 A CN1376072 A CN 1376072A CN 00806935 A CN00806935 A CN 00806935A CN 00806935 A CN00806935 A CN 00806935A CN 1376072 A CN1376072 A CN 1376072A
- Authority
- CN
- China
- Prior art keywords
- glp
- administration
- peptide
- ischemic
- glucagon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims (23)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/303,016 | 1999-04-30 | ||
US09/303,016 US6429197B1 (en) | 1998-10-08 | 1999-04-30 | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1376072A true CN1376072A (zh) | 2002-10-23 |
Family
ID=23170209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00806935A Pending CN1376072A (zh) | 1999-04-30 | 2000-05-01 | 利用胰高血糖素样肽-1或其生物活性类似物代谢介入以改善缺血性及再灌注大脑的功能 |
Country Status (14)
Country | Link |
---|---|
US (2) | US6429197B1 (zh) |
EP (1) | EP1187628B1 (zh) |
JP (1) | JP2002543145A (zh) |
CN (1) | CN1376072A (zh) |
AT (1) | ATE369873T1 (zh) |
AU (2) | AU774084B2 (zh) |
CA (1) | CA2368772C (zh) |
DE (1) | DE60035987T2 (zh) |
ES (1) | ES2290029T3 (zh) |
IL (1) | IL145829A0 (zh) |
MX (1) | MXPA01010937A (zh) |
NO (1) | NO20015298L (zh) |
NZ (1) | NZ514609A (zh) |
WO (1) | WO2000066142A2 (zh) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6849708B1 (en) * | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US7138486B2 (en) * | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US20060160740A1 (en) * | 1999-10-21 | 2006-07-20 | Suad Efendic | Use of GLP-1 or analogs in treatment of stroke |
MXPA02011339A (es) | 2000-05-19 | 2003-04-25 | Amylin Pharmaceuticals Inc | Tratamiento del sindrome coronario agudo con glp-1. |
DE60124710T2 (de) * | 2000-06-16 | 2007-09-13 | Eli Lilly And Co., Indianapolis | Analoge des glucagon ähnlichen peptid-1 |
US7090869B2 (en) | 2000-12-01 | 2006-08-15 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
JP2002293799A (ja) * | 2001-03-29 | 2002-10-09 | Itoham Foods Inc | 新規ペプチド及びそれを含有する消化管運動抑制剤 |
CA2455963C (en) * | 2001-07-31 | 2017-07-04 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1, exendin-4, peptide analogs and uses thereof |
DK1463751T3 (da) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albuminfusionsproteiner. |
WO2004071393A2 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r) |
ES2737835T3 (es) | 2003-04-23 | 2020-01-16 | Valeritas Inc | Bomba accionada hidráulicamente para la administración de medicamentos de larga duración |
US20080194483A1 (en) * | 2003-12-12 | 2008-08-14 | Brownlee Michael A | GLP-1 (9-36) methods and compositions |
WO2005060986A1 (en) * | 2003-12-12 | 2005-07-07 | Albert Einstein College Of Medicine Of Yeshiva University | Glp-1 (9-36) methods and compositions |
WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
AU2007233231B2 (en) | 2006-03-30 | 2011-02-24 | Mannkind Corporation | Multi-cartridge fluid delivery device |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
WO2010013012A2 (en) * | 2008-08-01 | 2010-02-04 | Lund University Bioscience Ab | Novel polypeptides and uses thereof |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
AU2009293019A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care Inc. | Solute concentration measurement device and related methods |
AU2010278894B2 (en) | 2009-07-30 | 2014-01-30 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN101706297B (zh) * | 2009-08-10 | 2012-10-17 | 浙江鼎立实业有限公司 | 数显式微压和微流量综合检测台 |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
JP6224586B2 (ja) | 2012-07-10 | 2017-11-01 | 武田薬品工業株式会社 | 注射用製剤 |
CN103566354B (zh) * | 2012-07-25 | 2017-12-05 | 江苏豪森药业集团有限公司 | 含有glp‑1类似物的衍生物或其可药用盐的药物组合物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
RU2015129788A (ru) | 2012-12-21 | 2017-01-30 | Санофи | Производные эксендина-4 как двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
KR102449167B1 (ko) * | 2016-05-06 | 2022-09-28 | 파세비오 파마수티컬스 인코포레이티드 | 제어된 지속 방출을 위한 elp 융합 단백질 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196196A (en) * | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
US4976959A (en) * | 1986-05-12 | 1990-12-11 | Burroughs Wellcome Co. | T-PA and SOD in limiting tissue damage |
US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5373016A (en) | 1993-05-28 | 1994-12-13 | Zeneca, Inc. | Protection of isothiazolinone biocides from free radicals |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
DK0996459T3 (da) | 1997-01-07 | 2006-01-16 | Amylin Pharmaceuticals Inc | Anvendelse af exendiner og agonister deraf til reduktion af födeindtagelse |
US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
AU6586298A (en) * | 1997-03-31 | 1998-10-22 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
MY155270A (en) * | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
NZ519752A (en) | 2000-10-20 | 2005-04-29 | Amylin Pharmaceuticals Inc | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide |
-
1999
- 1999-04-30 US US09/303,016 patent/US6429197B1/en not_active Ceased
-
2000
- 2000-05-01 AU AU46825/00A patent/AU774084B2/en not_active Ceased
- 2000-05-01 CA CA2368772A patent/CA2368772C/en not_active Expired - Fee Related
- 2000-05-01 AT AT00928616T patent/ATE369873T1/de not_active IP Right Cessation
- 2000-05-01 CN CN00806935A patent/CN1376072A/zh active Pending
- 2000-05-01 WO PCT/US2000/011652 patent/WO2000066142A2/en active Search and Examination
- 2000-05-01 MX MXPA01010937A patent/MXPA01010937A/es active IP Right Grant
- 2000-05-01 JP JP2000615026A patent/JP2002543145A/ja active Pending
- 2000-05-01 DE DE60035987T patent/DE60035987T2/de not_active Expired - Lifetime
- 2000-05-01 NZ NZ514609A patent/NZ514609A/xx not_active IP Right Cessation
- 2000-05-01 ES ES00928616T patent/ES2290029T3/es not_active Expired - Lifetime
- 2000-05-01 EP EP00928616A patent/EP1187628B1/en not_active Expired - Lifetime
- 2000-05-01 IL IL14582900A patent/IL145829A0/xx not_active IP Right Cessation
-
2001
- 2001-10-29 NO NO20015298A patent/NO20015298L/no not_active Application Discontinuation
-
2004
- 2004-08-06 US US10/913,309 patent/USRE41288E1/en not_active Expired - Lifetime
- 2004-09-15 AU AU2004212547A patent/AU2004212547B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO2000066142A3 (en) | 2002-01-24 |
AU774084B2 (en) | 2004-06-17 |
ES2290029T3 (es) | 2008-02-16 |
NO20015298D0 (no) | 2001-10-29 |
AU2004212547B2 (en) | 2008-03-20 |
CA2368772A1 (en) | 2000-11-09 |
JP2002543145A (ja) | 2002-12-17 |
IL145829A0 (en) | 2002-07-25 |
EP1187628A2 (en) | 2002-03-20 |
DE60035987D1 (de) | 2007-09-27 |
WO2000066142A2 (en) | 2000-11-09 |
NO20015298L (no) | 2001-12-28 |
AU4682500A (en) | 2000-11-17 |
AU2004212547A1 (en) | 2004-10-14 |
US6429197B1 (en) | 2002-08-06 |
EP1187628B1 (en) | 2007-08-15 |
ATE369873T1 (de) | 2007-09-15 |
CA2368772C (en) | 2011-11-15 |
USRE41288E1 (en) | 2010-04-27 |
NZ514609A (en) | 2004-03-26 |
DE60035987T2 (de) | 2008-05-08 |
MXPA01010937A (es) | 2002-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1376072A (zh) | 利用胰高血糖素样肽-1或其生物活性类似物代谢介入以改善缺血性及再灌注大脑的功能 | |
AU2004229049C1 (en) | Treatment Of Hibernating Myocardium Or Pulmonary Congestion | |
CN102753192B (zh) | 治疗代谢综合征的药物组合物 | |
US6391312B1 (en) | Remedies for diabetes | |
US6143718A (en) | Treatment of Type II diabetes mellutis with amylin agonists | |
RU2546520C2 (ru) | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа | |
EP0995440B1 (de) | Verfahren zur Stiegerung des Blutglukosespiegels in Säugern | |
DE60016393T2 (de) | Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe | |
CN1997383B (zh) | 含水母发光蛋白的组合物及使用它的方法 | |
Youngs | Hormonal control of pancreatic endocrine and exocrine secretion. | |
CN103893744A (zh) | 一种治疗糖尿病的药物制剂及其制备方法 | |
WO2021143879A1 (en) | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs | |
JPH0667832B2 (ja) | 腫瘍性疾患の治療に用いるプログルミド含有医薬組成物 | |
US5616558A (en) | Medicaments comprising glicentin as active ingredient | |
US20040156893A1 (en) | Method for treating hypothyroidism | |
LeRoith et al. | Type 2 diabetes: the role of basal insulin therapy | |
US20130090289A1 (en) | Method of Treatment of Type 2 Diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: EMELIN PHARMCEUTICAL INC Free format text: FORMER OWNER: BIOEBRASKA, INC. Effective date: 20031204 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20031204 Address after: American California Applicant after: Amylin Pharmaceuticals, Inc. Address before: Nebraska Applicant before: Bionebraska Inc. |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1050322 Country of ref document: HK |